Which is Better Farxiga vs Jardiance

Key Takeaway

If you have type 2 diabetes, heart failure, or chronic kidney disease, your doctor may have mentioned Farxiga (dapagliflozin) or Jardiance (empagliflozin). Both belong to the SGLT2 inhibitor class and are among the most clinically validated diabetes medications available today. Here is a quick look at how they compare:

• Both drugs lower blood sugar by blocking glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine.
• Jardiance has a stronger landmark cardiovascular outcome trial (EMPA-REG), reducing CV death by 38% in high-risk patients.
• Farxiga has broader FDA-approved indications, including heart failure with reduced AND preserved ejection fraction and CKD, even in non-diabetic patients.
• Side effects are largely similar: urinary tract infections, genital yeast infections, and rare diabetic ketoacidosis (DKA).
• Brand-name pricing in the US exceeds $600/month for both. Canadian online pharmacies can offer savings of 60-80% for eligible patients.
• Both drugs are endorsed by the American Diabetes Association (ADA), American College of Cardiology (ACC), and American Heart Association (AHA) for high-risk patients.

How Farxiga and Jardiance Work

Farxiga and Jardiance are both sodium-glucose cotransporter-2 (SGLT2) inhibitors. The SGLT2 protein is responsible for reabsorbing roughly 90% of filtered glucose back into the bloodstream from the kidneys. By blocking this transporter, both drugs allow excess glucose to pass into the urine rather than re-entering circulation, a process called glucosuria.

This mechanism has several downstream benefits:

• Blood sugar control: Consistently lowers HbA1c by approximately 0.5–1.0% without the risk of low blood sugar (hypoglycemia) when used alone.
• Weight loss: Patients typically lose 2–4 kg due to caloric loss through glucosuria, along with mild diuresis.
• Blood pressure reduction: Both agents modestly lower systolic blood pressure by 3–5 mmHg through natriuresis (sodium excretion).
• Heart and kidney protection: SGLT2 inhibitors reduce intraglomerular pressure, decrease cardiac preload and afterload, making them powerful beyond mere glucose lowering.

According to the Centers for Disease Control and Prevention (CDC), 38.4 million US adults (11.6%) have diabetes, and 35.5 million (1 in 7) live with chronic kidney disease. These overlapping populations stand to benefit enormously from SGLT2 inhibitors.

FDA-Approved Uses

While both medications share a common mechanism, their FDA-approved indications differ in meaningful ways. Understanding these distinctions is essential for both patients and prescribers.

Farxiga holds the distinction of being the first SGLT2 inhibitor FDA-approved to treat CKD in patients without diabetes, a landmark indication based on the DAPA-CKD trial. Jardiance’s EMPA-KIDNEY trial further validated the kidney benefits of empagliflozin across a wide spectrum of CKD patients.

The CDC reports that 6.7 million US adults are living with heart failure, and approximately half have preserved ejection fraction, a historically difficult-to-treat population now supported by both Farxiga and Jardiance.

Dosages and Administration

Both medications are taken once daily, orally, with or without food.

One important clinical note: Jardiance allows slightly broader use in patients with more advanced kidney disease when used for HF or CKD indications. Farxiga’s prescribing information for CKD permits use down to an eGFR of 25 mL/min/1.73m². Always consult FDA prescribing information and your healthcare provider for the most current guidance.

Side Effects and Risks

The side effect profiles of Farxiga and Jardiance are very similar due to their shared mechanism of action. The most frequently reported events are related to increased urinary glucose.

Common Side Effects (Both Drugs)

• Genital mycotic (yeast) infections, more common in women; approximately 6–9% incidence
• Urinary tract infections (UTIs), especially in patients prone to recurrent infections
• Increased urination (polyuria) and mild dehydration
• Dizziness, especially when standing (orthostatic hypotension), particularly in older adults or those on diuretics.
• Mild nausea or gastrointestinal discomfort at initiation

Serious but Rare Adverse Events

• Diabetic Ketoacidosis (DKA): Can occur even with near-normal blood glucose (euglycemic DKA). Risk increases during illness, fasting, surgery, or with carbohydrate restriction. FDA requires class warnings for both drugs.
• Fournier’s Gangrene: A rare but life-threatening necrotizing fasciitis of the genital area. Reported with all SGLT2 inhibitors. Seek immediate medical attention for any genital pain, swelling, redness, or fever.
• Acute Kidney Injury (AKI): Can occur in volume-depleted patients. Monitor renal function periodically, especially at initiation.
• Lower Limb Amputation: The FDA issued a warning for canagliflozin (Invokana); Farxiga and Jardiance appear to carry a lower risk, but the theoretical concern exists for high-risk patients (peripheral artery disease).
• Bone fractures: A theoretical concern, especially with long-term use in older adults. More studied with canagliflozin.

Per Drugs.com and Mayo Clinic prescribing guidance, patients should be instructed to hold both medications 3–4 days before any planned surgical procedure or prolonged fasting to reduce DKA risk.

Drug Interactions

Neither Farxiga nor Jardiance carries a large number of clinically significant drug interactions, but several merit attentions:

• Insulin and sulfonylureas: When combined with these agents, the risk of hypoglycemia increases. Dose adjustments of insulin or sulfonylureas (glipizide, glimepiride, etc.) are often required when starting SGLT2 inhibitor therapy.
• Diuretics (loop and thiazide): Additive diuretic effects increase risk of dehydration, volume depletion, and low blood pressure. Hydration status should be monitored closely, particularly in elderly patients.
• Lithium: SGLT2 inhibitors may increase lithium levels by promoting sodium and fluid loss, potentially causing lithium toxicity. Monitor lithium levels more frequently in patients on concurrent therapy.
• NSAIDs (ibuprofen, naproxen): Reduce renal blood flow and can worsen AKI risk, especially in volume-depleted patients already on SGLT2 therapy.
• ACE inhibitors/ARBs: These are often co-prescribed (especially for CKD or HF), and while safe and beneficial in combination, additive blood pressure lowering and kidney effects require monitoring.
• Antihypertensives: The blood-pressure-lowering effects of Farxiga and Jardiance may amplify hypotensive effects of antihypertensive agents.

Farxiga vs Jardiance Cost Comparison

Cost is one of the most pressing concerns for American patients managing chronic conditions, particularly seniors on fixed incomes and the uninsured. SGLT2 inhibitors remain brand-name-only in the United States, meaning no generic alternatives are yet available domestically.

Brand vs Generic Pricing

*Prices sourced from GoodRx.com and Doctorsolve.com

Manufacturer Copay & Patient Assistance Programs

Patient assistance programs and manufacturer coupons are designed to help patients reduce out-of-pocket expenses. However, these programs are often unreliable for long-term savings. They typically have strict eligibility criteria based on income level, insurance status, or citizenship. Additionally, coupons may expire, be discontinued without notice, or only provide temporary discounts that leave you paying full price later.

Get Farxiga and Jardiance from a Licensed Online Canadian Pharmacy – The Most Reliable Option

Unlike the temporary fixes and eligibility barriers of assistance programs, licensed Canadian pharmacies offer consistently affordable prices due to Canada’s government pricing regulations and controlled markups.

This makes them the most reliable long-term solution for U.S. patients seeking affordable medications.

For example, by using a trusted prescription referral service like DoctorSolve.com, Americans can safely access medications from licensed Canadian pharmacies. Through DoctorSolve, you can get Farxiga 10 mg for $256, a huge savings compared to typical U.S. prices of over $600 for the same quantity.

Best of all, these savings are consistent and available to everyone, regardless of income or insurance status, while maintaining safety and quality standards.

 You can buy Jardiance 25 mg online from a Canadian pharmacy through Doctorsolve.com

Farxiga and Jardiance Alternatives

SGLT2 inhibitors are not the only option for managing type 2 diabetes. Depending on individual health needs, cost considerations, kidney function, and tolerability, your doctor may discuss several alternatives:

Metformin

Metformin (Glucophage) is a low-cost ($4–$10/month generic), well-tolerated first-line option for many with type 2 diabetes, backed by decades of safety data. However, the 2026 ADA Standards recommend personalized initial therapy: GLP-1 RAs or SGLT2 inhibitors for those with heart disease, heart failure, CKD, or obesity; metformin for others without these risks. Unlike SGLT2 inhibitors, metformin does not offer proven cardiovascular or kidney protection. It is contraindicated with significant kidney impairment (eGFR <30 mL/min/1.73 m²).

 You can buy Metformin 850 mg online for as low as $0.43 per tablet from a Canadian pharmacy through Doctorsolve.com

Invokana (Canagliflozin)

Invokana was the first SGLT2 inhibitor approved in the US (2013) and offers similar benefits to Farxiga and Jardiance. It carries FDA warnings (no longer boxed) for increased risk of lower-limb amputations and bone fractures, which has somewhat limited its use compared to the others. The CREDENCE trial showed strong kidney protection in patients with type 2 diabetes and diabetic nephropathy.

You can buy Invokana 300 mg online for as low as $3.30 per tablet from a Canadian pharmacy through Doctorsolve.com

Januvia (Sitagliptin)

Januvia, a DPP-4 inhibitor, provides modest blood sugar lowering with low hypoglycemia risk and weight neutrality. It lacks the cardiovascular or renal outcome benefits of SGLT2 inhibitors and is often chosen for patients intolerant to those agents. Generic sitagliptin became available in 2026 (not 2023), significantly lowering costs.

You can buy Sitagliptin 100 mg online for as low as $0.92 per tablet from a Canadian pharmacy through Doctorsolve.com

Onglyza (Saxagliptin)

Onglyza (saxagliptin), another DPP-4 inhibitor, showed increased heart failure hospitalizations in the SAVOR-TIMI 53 trial, leading to an FDA warning. It is generally avoided or used cautiously in patients with or at high risk for heart failure and is less commonly prescribed than other DPP-4 inhibitors.

You can buy Saxagliptin 5 mg online for as low as $2.59 per tablet from a Canadian pharmacy through Doctorsolve.com

Frequently Asked Questions

What is better, Farxiga or Jardiance?

Neither drug is universally “better”, the right choice depends on your specific health needs. Jardiance has a more established cardiovascular mortality benefit based on the landmark EMPA-REG OUTCOME trial, which demonstrated a 38% reduction in CV death in high-risk patients with type 2 diabetes and established cardiovascular disease (Zinman et al., 2015, NEJM). Farxiga has broader FDA-approved indications, including CKD without diabetes and heart failure with preserved ejection fraction. The ADA, AHA, and ACC now consider both first-line options for patients with type 2 diabetes who also have heart failure or CKD. Discuss with your doctor which fits your clinical profile.

Why would a doctor prescribe Farxiga?

Doctors commonly prescribe Farxiga for multiple reasons: to lower blood sugar in type 2 diabetes, to reduce hospitalizations and death in heart failure (both HFrEF and HFpEF), and to slow the progression of chronic kidney disease, even in patients without diabetes. The DAPA-HF trial found that Farxiga cut the combined risk of worsening heart failure or cardiovascular death by 26% compared to placebo (McMurray et al., 2019, NEJM). The DAPA-CKD trial similarly showed a 39% reduction in the composite risk of kidney function decline, kidney failure, or death in CKD patients.

What is the downside of taking Jardiance?

The most common downsides of Jardiance include genital yeast infections, urinary tract infections, and increased urination. Rarely, serious events such as diabetic ketoacidosis (DKA), Fournier’s gangrene, or acute kidney injury can occur. Jardiance should be paused before surgery or prolonged fasting. Cost is another significant barrier; US retail pricing exceeds $600/month without insurance or assistance programs. Some patients experience light-headedness or dehydration, especially when also taking diuretics. As with all SGLT2 inhibitors, it is not appropriate for patients with type 1 diabetes due to elevated DKA risk.

What are the main side effects of Farxiga and Jardiance?

The most common side effects for both drugs are similar: genital mycotic (yeast) infections (especially in women), urinary tract infections, frequent urination, and mild dehydration. These typically improve over time. More serious but rare risks include euglycemic diabetic ketoacidosis, Fournier’s gangrene (necrotizing perineal infection), and acute kidney injury in dehydrated patients. Both medications can cause a modest drop in blood pressure, which may cause dizziness when standing. Report any unusual genital symptoms, severe abdominal pain, difficulty breathing, or signs of dehydration to your doctor promptly.

Can you take Farxiga and Jardiance together?

No. Farxiga and Jardiance should not be taken together. Both are SGLT2 inhibitors that work through the exact same mechanism, combining them would provide no additional benefit while significantly increasing the risk of side effects including dehydration, low blood pressure, UTIs, genital infections, and DKA. If one SGLT2 inhibitor is not providing adequate glycemic control or is poorly tolerated, your doctor may switch you to the other or add a different class of medication (such as a GLP-1 agonist, DPP-4 inhibitor, or insulin) rather than combining two SGLT2 inhibitors.

References and Citations

The following authoritative sources were used in the preparation of this article:

1. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report. Available at: https://www.cdc.gov
2. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). N Engl J Med. 2019; 381:1995-2008.
3. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015; 373:2117-2128.
4. Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020; 383:1436-1446.
5. Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved). N Engl J Med. 2021; 385:1451-1461.
6. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023; 388:117-127.
7. US Food and Drug Administration (FDA). Farxiga Prescribing Information. Available at: https://www.fda.gov
8. US Food and Drug Administration (FDA). Jardiance Prescribing Information. Available at: https://www.fda.gov
9. Farxiga and Jardiance pricing. Available at: https://www.goodrx.com
10. com. International drug price comparison. Available at: https://www.pharmacychecker.com
11. com. Farxiga and Jardiance drug monographs. Available at: https://www.drugs.com
12. Mayo Clinic. SGLT2 inhibitors for type 2 diabetes. Available at: https://www.mayoclinic.org
13. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024.
14. National Diabetes Statistics Report. https://www.cdc.gov/diabetes/php/data-research/index.html
15. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Statistics. https://www.niddk.nih.gov/health-information/health-statistics/diabetes-statistics
16. Diabetes. https://www.cdc.gov/nchs/fastats/diabetes.htm
17. American Diabetes Association. Statistics About Diabetes. https://diabetes.org/about-diabetes/statistics/about-diabetes
18. World Population Review. Diabetes Rates by Country 2026. https://worldpopulationreview.com/country-rankings/diabetes-rates-by-country
19. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin
20. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious
21. Proceed With Caution with These 6 Jardiance Interactions. https://www.goodrx.com/jardiance/what-drugs-should-not-be-taken-with-jardiance
22. PubMed Central. Summary of Revisions: Standards of Care in Diabetes—2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12690167/
23. Duke Health. FDA Adds Boxed Warning to Type 2 Diabetes Medication Canagliflozin. https://phmo.dukehealth.org/news/fda-adds-boxed-warning-type-2-diabetes-medication-canagliflozin
24. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine
25. FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin
26. Medical News Today. Jardiance interactions: Alcohol, medications, and other factors. https://www.medicalnewstoday.com/articles/drugs-jardiance-interactions
27. Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s026lbl.pdf
28. Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202293s031lbl.pdf